Is KL003 gene therapy available in China?

Yes. KL003 is listed in the Boao Lecheng International Medical Tourism Pilot Zone directory and is associated with Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital. This is a pilot-zone pathway, not nationwide approval.

Who may qualify for KL003?

The stated criteria are patients aged 7–55 with transfusion-dependent β-thalassemia. The attending physician evaluates suitability based on genotype, medical history, and overall condition.

How much does KL003 gene therapy cost in China?

An official price has not yet been set. There is therefore no confirmed USD treatment price at present. Patients should confirm current pricing directly with the hospital.

Can international patients explore KL003 treatment in China?

International patients can explore the treatment pathway through medical review and hospital coordination. Actual eligibility and access depend on physician assessment and the applicable pilot-zone requirements.

top of page

FREE CONSULTATION

ChinaCurelink
a MedeboundHEALTH Company

Gene-Modified HSC Therapy (KL003) for Transfusion-Dependent β-Thalassemia in China: 2026 International Patient Guide to Thalassemia Gene Therapy China

ChinaCureLink

Tue Sep 01 2026

6 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page